Major trials of the effects of lowering LDL cholesterol among diabetic patients without pre-existing CHD †
| Trial2-150 | Type of diabetic patient | Cholesterol lowering treatment comparison | Approx number of CHD events/diabetic patients without pre-existing CHD |
Scheduled end date |
| HPS | Type 1 and 2 (see table 1) | Simvastatin 40 mg dailyv placebo | 300/4000 | 2001 |
| ALLHAT | Type 2 with hypertension | Pravastatin 40 mg dailyv usual care | 250/3500 | 2002 |
| ASPEN | Type 2 with one risk factor | Atorvastatin 10 mg dailyv placebo | 300/2000 | 2003 |
| CARDS | Type 2 with one risk factor | Atorvastatin 10 mg dailyv placebo | 300/3000 | 2004 |
| ASCOT | Type 2 with hypertension and two other risk factors | Atorvastatin 10 mg daily vplacebo | 200/4000 | 2004 |
| LDS | Type 2 | Cerivastatin 0.4 mg daily v placebo (and, in factorial design, fenofibrate vplacebo) | 450/5000 | 2005 |
↵2-150 See box for explanation of trial acronyms.
†Trials with at least 100 CHD events expected during about 5 years of ⩾ 1.0 mmol/l difference in LDL cholesterol.